research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Cocaine should not be used in individuals with a known allergy or hypersensitivity to the drug or any components of its topical formulation. It is also contraindicated in elderly patients and those with a history of hypertension or cardiovascular disease.
=== Fragmentation rules summary === Most fragment ions are b- or y-ions. a-ions are also frequently seen by the loss of CO from b-ions. Satellite ions(wn, vn, dn-ions) are formed by high-energy CID. Ser-, Thr-, Asp- and Glu-containing ions generate neutral molecular loss of water (-18). Asn-, Gln-, Lys-, Arg-containing ions generate neutral molecular loss of ammonia (-17). Neutral loss of ammonia from Arg leads to fragment ions (y-17) or (b-17) ions with higher abundance than their corresponding ions. When C-terminus has a basic residue, the peptide generates (bn-1+18) ion. A complementary b-y ion pair can be observed in multiply charged ions spectra. For this b-y ion pair, the sum of their subscripts is equal to the total number of amino acid residues in the unknown peptide. If the C-terminus is Arg or Lys, y1-ion can be found in the spectrum to prove it.
=== Delivery vans === UPS refers to its delivery van as a "package car". Several designs and sizes are used by the company, dependent on routes and package volume; the distinct design of the rounded "bubble-nose" front hood and upper roofline was introduced in 1965. The bodies of the package cars are manufactured by Morgan Olson (Grumman Olson), Union City Body, and Utilimaster; while older vehicles were based on Ford or General Motors P-chassis, vehicles manufactured in the 21st century use Freightliner or Workhorse chassis. Until the end of the 20th century, UPS delivery vehicles were equipped with manual transmissions and steering, with automatic transmissions and power steering adopted by newer vehicles. For lower-volume delivery routes, UPS utilizes production-based vehicles, including minivans (including the Ford Transit Connect or the Ford Transit, and Dodge Grand Caravan C/V) and Mercedes-Benz (Dodge/Freightliner) Sprinter box vans. UPS has ordered Modec electric vans for its UK and German fleets. Energy costs play a huge part in the potential profitability of package delivery companies.
Sport in modern India is a nexus of little-known indigenous traditions and commercial sporting events with worldwide reach. Traditional sports such as kabaddi and kho-kho have experienced a resurgence, attracting large television audiences; on the other hand, kushti wrestling in rural akharas—often regarded by its practitioners as not so much a sport as a physical and moral regimen—has continued to survive away from the exposure of broadcasting. Cricket is India's most watched sport and a multi-billion dollar industry. The widespread popularity of chess among youth in southern India culminated in 18-year-old Gukesh Dommaraju of Chennai winning the undisputed World Chess Champion title in 2024. British intervention reshaped India's athletic landscape. It introduced cricket, football and field hockey and institutionalised polo—a sport whose history is a case of reverse migration from India to the West. Today, at the rural grassroots level, government initiatives like "Khelo India" have democratised athletics for traditionally overlooked youth. Rural soccer programs have employed teamwork to break down old caste barriers. State initiatives such as the Target Olympic Podium Scheme have expanded resources for female athletes; meanwhile, the prominent international victories of figures like boxer Mary Kom and badminton player P. V. Sindhu have challenged traditional gender stereotypes in sports. India has won eight men's cricket ICC tournament titles: two Cricket World Cups, three T20 World Cups, and three Champions Trophy titles.
Sources: en.wikipedia.org
That December the headquarters of the 4th Ferrying Group of the Army Air Forces Air Transport Command shifted to the airport. The group was tasked with sending new aircraft overseas; pilots departed Memphis for South America and then flew over the South Atlantic Ocean to Africa. Personnel such as mechanics and engineers underwent training at the base and then traveled overseas. Chicago and Southern's repair facilities at the airport were used to repair military planes. Commercial air service continued, though it was limited. The ferrying group's postwar activities included moving planes off deactivated bases. For a period in 1946, Memphis served as headquarters for the Continental Division of the Air Transport Command, which oversaw the 4th Ferrying Group and ran scheduled flights for military personnel throughout the country. The ferrying group ceased operations in March 1947. City officials reached an agreement with the federal government in January 1949 to regain control of the airfield. Five trunk carriers flew to Memphis as of 1947, and two years later, a regional airline named Southern Airways launched operations with multi-stop service to Atlanta. The airport opened the first air-cargo terminal in the country in February 1958. The following year, passenger counts crossed one million. In August 1960, the city received its first scheduled jet flight; Delta Air Lines started using Convair 880s on its Chicago–Memphis–New Orleans route. The United States Supreme Court in Turner v. City of Memphis ordered the desegregation of the airport in 1962.
Another approach of making Sendai virus non-pathogenic included the short-term treatment of the virions with ultraviolet light. Such treatment causes a loss of the virus replication ability. However, even this replication-deficient virus can induce the cancer cells death and stimulate anti-tumor immunity. It can trigger extensive apoptosis of human glioblastoma cells in culture, and it can efficiently suppress the growth of these cells in model animals. The ultraviolet light treated virus can also kill human prostate cancer cells in culture by triggering their apoptosis and eradicate tumors that originated from these cells in immunodeficient model animals. Moreover, it can stimulate immunomodulated tumor regression of colon and kidney cancers in immunocompetent mice. Similar regressions caused by the replication-deficient Sendai virus have been observed in animals with transplanted melanoma tumors.
Th22 cells (T helper cells type 22) are subpopulation of CD4+ T cells that produce interleukin-22 (IL-22). They play a role in the protective mechanisms against variety of bacterial pathogens, tissue repair and wound healing, and also in pathologic processes, including inflammations, autoimmunity, tumors, and digestive organs damages.
The active site of human ADH1 (PDB:1HSO) consists of a zinc atom, His-67, Cys-174, Cys-46, Thr-48, His-51, Ile-269, Val-292, Ala-317, and Phe-319. In the commonly studied horse liver isoform, Thr-48 is a Ser, and Leu-319 is a Phe. The zinc coordinates the substrate (alcohol). The zinc is coordinated by Cys-46, Cys-174, and His-67. Leu-319, Ala-317, His-51, Ile-269 and Val-292 stabilize NAD+ by forming hydrogen bonds. His-51 and Ile-269 form hydrogen bonds with the alcohols on nicotinamide ribose. Phe-319, Ala-317 and Val-292 form hydrogen bonds with the amide on NAD+.
=== Recursive directional ligation (RDL) === In recursive directional ligation, the gene encoding the monomer is inserted into a plasmid with restriction sites that are recognized by at least two endonucleases. The endonucleases will cut the plasmid, releasing the gene of interest. Then, this single gene is inserted into a recipient plasmid vector already containing one copy of the ELP monomer gene via digestion of the recipient plasmid with the same restriction endonucleases used on the donor plasmid and a subsequent ligation step. From this process, a sequence of two ELP monomer genes is retrieved. RDL allows for the controlled synthesis of ELP gene oligomers, in which single gene segments are sequentially added. However, the restriction endonucleases used are limited to those that do not cut within the ELP monomer gene itself, as this would lead to loss of crucial nucleotides and a potential frameshift mutation in the protein.
Sources: en.wikipedia.org
== Synthesis == The goal of any synthetic method for nanomaterials is to yield a material that exhibits properties that are a result of their characteristic length scale being in the nanometer range (1 – 100 nm). Accordingly, the synthetic method should exhibit control of size in this range so that one property or another can be attained. Often the methods are divided into two main types, "bottom up" and "top down".
Eukaryotic chloroplasts contain a multi-subunit RNAP ("PEP, plastid-encoded polymerase"). Due to its bacterial origin, the organization of PEP resembles that of current bacterial RNA polymerases: It is encoded by the RPOA, RPOB, RPOC1 and RPOC2 genes on the plastome, which as proteins form the core subunits of PEP, respectively named α, β, β′ and β″. Similar to the RNA polymerase in E. coli, PEP requires the presence of sigma (σ) factors for the recognition of its promoters, containing the -10 and -35 motifs. Despite the many commonalities between plant organellar and bacterial RNA polymerases and their structure, PEP additionally requires the association of a number of nuclear encoded proteins, termed PAPs (PEP-associated proteins), which form essential components that are closely associated with the PEP complex in plants. Initially, a group consisting of 10 PAPs was identified through biochemical methods, which was later extended to 12 PAPs. Chloroplast also contain a second, structurally and mechanistically unrelated, single-subunit RNAP ("nucleus-encoded polymerase, NEP"). Eukaryotic mitochondria use POLRMT (human), a nucleus-encoded single-subunit RNAP. Such phage-like polymerases are referred to as RpoT in plants.
There is also in vitro evidence of synergy for colistimethate sodium used in combination with other antipseudomonal antibiotics. Colistimethate sodium aerosol (Promixin; Colomycin Injection) is used to treat pulmonary infections, especially in cystic fibrosis. In the UK, the recommended adult dose is 1–2 million units (80–160 mg) nebulised colistimethate twice daily. Nebulized colistin has also been used to decrease severe exacerbations in patients with chronic obstructive pulmonary disease and infection with Pseudomonas aeruginosa.
== Applications == Research into the AMP family—particularly in regards to their mechanism of action—has been ongoing for nearly 20 years. Despite sustained interest, treatments derived or utilizing AMPs have not been widely adopted for clinical use for several reasons. One, drug candidates from AMPs have a narrow window of bioavailability, because peptides are quickly broken down by proteases. Two, peptide drugs are more expensive than small molecule drugs to produce, which is problematic since peptide drugs must be given in large doses to counter rapid enzymatic breakdown. These qualities also limit routes of administration, typically to injection, infusion, or slow release therapy. Research into new and improved variations derived from cathelicidin continues.
During the lockdown Gavin suggested, 'Why don't we record these things so we've at least got studio recordings of this material?' That doesn't mean we're going to make a new album or it's ever gonna come out, but we have started this process." In a November 2024 interview with Louder Sound, Jakszyk was questioned about the band's future and mentioned the possibility of new studio recordings being released, stating: "The honest answer is, you'll have to ask Robert. It's all in his hands. He's retired a million times before, but he is 78. One of the things we have been doing of late is recording studio versions of the new material [only previously played live]. We've used the live recordings as a template, and I've done guitars, overdubs and backing vocals. Whether that comes out as a King Crimson album or whether it lies in the vaults, I don't know." Eight months later, in a July 2025 interview with Goldmine magazine, Jakszyk stated that "as we speak, we're doing a King Crimson studio album" and confirmed that it featured the most recent band line-up. He cautioned "when that will come out and what format or how — that's beyond my brief. But yeah, we've been doing it piecemeal, and then a couple of months ago, the management said, 'Can we?' So, yeah. I've been recording that with a view to it coming out in some format at some point. But who knows when?... There also are future plans for some live film of us playing in various places. There's an ongoing thread.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.